STOCK CAPITAL (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Dec. 31, 2025 |
| STOCKHOLDERS' DEFICIT |
|
|
| Summary of the Company's option activity |
| | | | | | | | | For the Three months ended | | | March 31, 2026 | | | | | Weighted | | | | | | | average | | Aggregate | | | Amount of | | exercise | | intrinsic | | | options * | | price | | value | | | | | $ | | $ | Outstanding at December 31, 2025 | | 51,656 | | 34.19 | | — | Granted | | — | | — | | — | Vested | | (400) | | 25.95 | | — | Outstanding at March 31, 2026 | | 51,256 | | 34.25 | | — | Exercisable at March 31, 2026 | | 43,934 | | 34.36 | | — |
* Represents Employee Stock Options only (not including RSUs).
|
| | | | | | | | | | | | | | | For the year ended December 31, | | | 2025 | | 2024 | | | | | Weighted | | | | | | Weighted | | | | | Amount | | average | | Aggregate | | Amount | | average | | Aggregate | | | Of | | exercise | | Intrinsic | | Of | | exercise | | intrinsic | | | options(*) | | price | | Value | | Options(*) | | Price | | value | | | | | $ | | $ | | | | $ | | $ | Outstanding at beginning of period | | 86,359 | | 34.55 | | | | 107,052 | | 49.01 | | | Granted | | — | | — | | | | — | | — | | | Exercised | | — | | — | | | | — | | — | | | Forfeited | | (34,703) | | 35.09 | | | | (20,693) | | 109.34 | | | Outstanding at end of period | | 51,656 | | 34.19 | | — | | 86,359 | | 34.55 | | — | Vested at end of period | | 43,800 | | 34.39 | | — | | 69,176 | | 34.81 | | — |
* Represents Employee Stock Options only (not including RSUs).
|
| Schedule of options outstanding have been separated into exercise prices |
|
| | | | | | | | | | | | | | | | | | | Weighted average | | | | | | | | | | | remaining | | | | | | | | | | | contractual | | Options | Exercise | | Options outstanding | | Life - Years | | exercisable as of | price | | As of December 31, | | As of December 31, | | As of December 31, | $ () | * | 2025 | | 2024 | | 2025 | | 2024 | | 2025 | | 2024 | 11.25 | | 26,989 | | 30,011 | | 4.15 | | 4.70 | | 26,989 | | 30,011 | 25.95 | | 13,213 | | 17,693 | | 7.60 | | 8.60 | | 6,940 | | 4,423 | 36.75 | | — | | 24,641 | | — | | 0.75 | | — | | 24,641 | 45.60 | | — | | 1,760 | | — | | 7.18 | | — | | 1,210 | 61.35 | | 6,327 | | 6,727 | | 6.72 | | 7.72 | | 4,744 | | 3,364 | 142.65 | | 5,127 | | 5,527 | | 4.81 | | 5.81 | | 5,127 | | 5,527 | | | 51,656 | | 86,359 | | 5.41 | | 4.73 | | 43,800 | | 69,176 |
|
| Schedule of restricted stock activity |
| | | | | | | | | | | | | Weighted Average | | | | | | | Remaining | | | Number of Shares | | Weighted Average | | Contractual | | | of Restricted | | Grant Date Fair | | Term | | | Stock | | Value | | (Years) | Nonvested as of December 31, 2025 | | 310,854 | | 3.01 | | 0.45 | Granted | | — | | — | | — | Vested | | 57,605 | | 4.95 | | — | Forfeited | | — | | — | | — | Nonvested as of March 31, 2026 | | 253,249 | | 2.57 | | 0.26 |
|
| | | | | | | | | | | | | Weighted | | | | | | | Average | | | Number of | | Weighted | | Remaining | | | Restricted | | Average Grant | | Contractual | | | Stock | | Date Fair Value | | Term (Years) | Nonvested as of December 31, 2023 | | 20,327 | | (*) 42.90 | | 1.32 | Granted | | 115,210 | | (*) 4.95 | | | Vested | | 6,679 | | (*) 38.73 | | | Forfeited | | 7,572 | | (*)31.11 | | | Nonvested as of December 31, 2024 | | 121,286 | | 6.69 | | 0.72 | Granted | | 688,666 | | 2.14 | | | Vested | | 469,098 | | 2.74 | | | Forfeited | | 30,000 | | 2.14 | | | Nonvested as of December 31, 2025 | | 310,854 | | 3.01 | | 0.45 |
|
| Schedule of total stock-based compensation expense |
| | | | | | | | | Three months ended | | | May 31, | | | 2026 | | 2025 | Research and development | | $ | 63 | | $ | 247 | General and administrative | | | 70 | | | 470 | Total stock-based compensation expense | | $ | 133 | | $ | 717 |
|
| | | | | | | | | December 31, | | | 2025 | | 2024 | | | | U.S. $ in thousands | Research and development | | | 571 | | | 355 | General and administrative | | | 949 | | | 343 | Total stock-based compensation expense | | | 1,520 | | | 698 |
|